The selective ADRA2A agonist guanfacine is used in the treatment of ADHD, consistent with a potential involvement of ADRA2A in the pathophysiology of the disorder (Arnsten and Pliszka 2011). This evidence concerns the gene ADRA2A and attention deficit-hyperactivity disorder.